Valuation: MultiCell Technologies, Inc.

Market Cap 1.5M 1.32M 1.25M 1.13M 2.13M 144M 2.14M 14.94M 5.77M 73.49M 5.63M 5.51M 236M P/E 2013
-1.09x
P/E 2014 -4.9x
Enterprise Value 1.59M 1.4M 1.32M 1.2M 2.25M 153M 2.27M 15.84M 6.12M 77.9M 5.97M 5.84M 250M EV / Sales 2013
34.9x
EV / Sales 2014 45.7x
Free-Float
90.01%
Yield 2013 *
-
Yield 2014 -
1 week 0
Extreme 1.0E-6
0
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0
5 years 0
Extreme 1.0E-6
0
10 years 0
Extreme 1.0E-6
0.01
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 5K
+2.64%+7.07%+11.87%+38.40% 47.97B
+0.22%+0.40%+50.91%+37.06% 44.5B
-1.58%+5.65%+359.34%+598.06% 43.93B
+1.70%+4.61%+12.56%+90.97% 41.03B
+0.51%-0.61%+5.18%+46.87% 29.85B
-0.48%+0.59%+23.98%+148.36% 17.27B
+0.08%+9.30%+8.41% - 15.34B
+1.76%+0.85%+29.13%+48.42% 15.3B
+1.97%-2.82% - - 14.82B
Average +0.68%+2.10%+62.67%+144.02% 27B
Weighted average by Cap. +0.74%+2.79%+79.47%+159.26%

Financials

2013 2014
Net sales 49.32K 43.38K 41.02K 37.2K 69.87K 4.73M 70.27K 491K 190K 2.42M 185K 181K 7.76M 49.32K 43.38K 41.02K 37.2K 69.87K 4.73M 70.27K 491K 190K 2.42M 185K 181K 7.76M
Net income -1.23M -1.09M -1.03M -931K -1.75M -119M -1.76M -12.29M -4.75M -60.47M -4.64M -4.53M -194M -380K -334K -316K -287K -538K -36.48M -542K -3.78M -1.46M -18.62M -1.43M -1.4M -59.82M
Net Debt -39.11K -34.4K -32.53K -29.5K -55.4K -3.75M -55.73K -389K -150K -1.92M -147K -144K -6.16M 90.04K 79.19K 74.89K 67.92K 128K 8.64M 128K 897K 346K 4.41M 338K 331K 14.17M
Logo MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company. The Company and its subsidiaries are developing therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer and interventional cardiology, and peripheral vessel applications. The Company's portfolio of lead drug candidates is in various stages of discovery optimization, and preclinical and clinical development, and includes MCT-125, MCT-465, MCT-475 and MCT-485. MCT-125 is a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue. MCT-465 is a preclinical synthetic double-stranded ribonucleic acid (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers. MCT-475 is a discovery-stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers. MCT-485 is a discovery-stage dsRNA therapeutic candidate for the treatment of certain cancers.
Employees
2
Date Price Change Volume
26-09-25 US$0.000001 0.00% 1,000
26-09-23 US$0.000001 0.00% 38,000
  1. Stock Market
  2. Stocks
  3. MCET Stock